NCT00387335 · REGISTRY CONDITION SEARCH

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2014-07-25

This phase II trial is studying how well sunitinib works in treating patients with recurrent and/or metastatic head and neck cancer. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria

→

outcome · POSTED

Feasibility of Treatment

→

outcome · POSTED

Progression-free Survival

→

outcome · POSTED

Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Criteria: * Hemoglobin \>= 9 g/dL * Histologically or cytologically confirmed squamous cell carcinoma of the head and neck: * Recurrent and/or metastatic disease * Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 20 mm with conventional techniques OR as \>= 10 mm with spiral CT scan * No known brain metastases * Life expectancy \>= 2 months * ECOG performance status (PS) 0-1 or Karnofsky PS 70-100% (for patients in cohort A) * ECOG PS 2 or Karnofsky PS 60-70% (for patients in cohort B) * WBC \>= 3,000/mm\^3 * Absolute neutrophil count \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Calcium =\< 12.0 mg/dL * Bilirubin normal * AST and ALT =\< 2.5 times upper limit of normal * Creatinine normal OR creatinine clearance \>= 60 mL/min * QTc \< 500 msec * No New York Heart Association class III or IV heart failure: * Patients with the following are eligible provided they have New York Heart Association class II cardiac function on baseline ECHO/MUGA: * History of class II heart failure and asymptomatic on treatment * Prior anthracycline exposure * Prior central thoracic radiation that included the heart in the radiotherapy port * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No history of allergic reactions to compounds of similar chemical or biological composition to sunitinib malate * No history of serious ventricular arrhythmia (i.e., ventricular fibrillation or ventricular tachycardia \>= 3 beats in a row) * No history of other significant ECG abnormalities * No uncontrolled hypertension (defined as systolic blood pressure \[BP\] \>= 140 mm Hg or diastolic BP \>= 90 mm Hg) * No condition resulting in an inability to take oral medication, including any of the following: * Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation * Active peptic ulcer disease * No gastrostomy, jejunostomy, or other forms of enteral tube-feeding modalities * No serious or nonhealing wound, ulcer, or bone fracture * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * No cerebrovascular accident or transient ischemic attack within the past 12 months * No myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 12 months * No pulmonary embolism within the past 12 months * No pre-existing uncontrolled thyroid abnormality (i.e., inability to maintain thyroid function within the normal range with medication) * No uncontrolled intercurrent illness, including either of the following: * Ongoing or active infection * Psychiatric illness or social situation that would limit compliance with study requirement * No more than two prior regimens for recurrent or metastatic disease: * Prior chemotherapy as part of initial curative intent therapy (e.g., neoadjuvant, adjuvant, or concurrent chemoradiotherapy) is allowed and will not count as prior therapy for recurrent or metastatic disease * At least 4 weeks since prior major surgery * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered * At least 4 weeks since prior radiotherapy * No prior treatment with any other antiangiogenic agent (e.g., bevacizumab, sorafenib, pazopanib, AZD2171, vatalanib, or VEGF Trap) * No prior surgical procedure affecting absorption * At least 7 days since prior and no concurrent use of CYP3A4 inhibitors, including any of the following: * Azole antifungals (e.g., ketoconazole, itraconazole) * Verapamil * Clarithromycin * HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir, nelfinavir) * Erythromycin * Delavirdine * Diltiazem * At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the following: * Rifampin * Phenytoin * Rifabutin * Hypericum perforatum (St. John's wort) * Carbamazepine * Efavirenz * Phenobarbital * Tipranavir * No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin): Concurrent dosing of =\< 2 mg of warfarin daily for prophylaxis of thrombosis is allowed; Concurrent low molecular weight heparin allowed provided prothrombin time INR is =\< 1.5 * No other concurrent investigational agents * No concurrent agents with proarrhythmic potential, including any of the following: * Terfenadine * Quinidine * Procainamide * Disopyramide * Sotalol * Probucol * Bepridil * Haloperidol * Risperidone * Indapamide * Flecainide * No other concurrent anticancer agents or therapies * No concurrent combination antiretroviral therapy for HIV-positive patients
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: sunitinib malate
label
Arm I
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I
description
Given orally
name
sunitinib malate
other Names
SU11248
sunitinib
Sutent
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 22
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
measure
Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria
time Frame
While patient remains on treatment, up to 30 weeks
description
Ability to remain on treatment without dose reduction
measure
Feasibility of Treatment
time Frame
While patient remains on treatment, up to 30 weeks

secondary Outcomes

description
Time to disease progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
measure
Progression-free Survival
time Frame
Up to 2 years
description
Time from start of treatment until death from any cause.
measure
Overall Survival
time Frame
Up to two years

Full study description

brief Summary: This phase II trial is studying how well sunitinib works in treating patients with recurrent and/or metastatic head and neck cancer. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
detailed Description: OBJECTIVES: I. Determine the overall response rate of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with sunitinib malate. II. Determine the toxicity of this drug in these patients. III. Determine the feasibility of administering this drug to patients with ECOG performance status 2 (cohort B). OUTLINE: This is a multicenter, cohort study. Patients are assigned to one of two cohorts according to ECOG performance status (ECOG 0-1 \[cohort A\] vs ECOG 2 \[cohort B\]). Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for at least 1 year.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-24ec59ed30a4d2eb9f93
requested nct id
NCT00387335
primary nct id
NCT00387335
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
payload sha256
698fc7cf2b58629be16cff75da89a8dbb2a425777a55f23fc5b202745e7782d8
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-24ec59ed30a4d2eb9f93
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00387335
occurrences
context exact
NCT00387335
end
11
exact text
NCT00387335
start
0
offset unit
unicode_code_points
query cond
Hypopharyngeal Cancer
query disease state id
ds-hypopharyngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
source json pointer
/studies/14/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
5dddcf186d91b2724d6b97753cfe00867b6907d50c4a6e25ac1a941152dc43b5
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-3f02046083362ace9eb2
requested nct id
NCT00387335
primary nct id
NCT00387335
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
17d83f3256de91ac7f6fb5737eee486f312338af742370bacf3f5c2113cc402e
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-3f02046083362ace9eb2
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00387335
occurrences
context exact
NCT00387335
end
11
exact text
NCT00387335
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/22/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
5dddcf186d91b2724d6b97753cfe00867b6907d50c4a6e25ac1a941152dc43b5
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-4304ed32c073df3bf00c
requested nct id
NCT00387335
primary nct id
NCT00387335
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
payload sha256
0248bcc673c59c753cae5587e15b9e1f21eaf8ea67ac173fd343b75831e38f1e
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-4304ed32c073df3bf00c
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00387335
occurrences
context exact
NCT00387335
end
11
exact text
NCT00387335
start
0
offset unit
unicode_code_points
query cond
Metastatic Squamous Neck Cancer With Occult Primary
query disease state id
ds-metastatic-squamous-neck-cancer-with-occult-primary
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-metastatic-squamous-neck-cancer-with-occult-primary-000.json
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
source json pointer
/studies/6/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
5dddcf186d91b2724d6b97753cfe00867b6907d50c4a6e25ac1a941152dc43b5
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice